60MO Real-world overall and progression-free survival for first-line immunotherapy-based regimens in advanced non-small cell lung cancer. (December 2022) - Waterhouse, D.M.; Ray, S.; Betts, K.A.; Yuan, Y.; Yin, L.; Gao, S.; Sundar, M.; Stenehjem, D.